Pharmaceutics (Feb 2023)

Preclinical PET Imaging and Toxicity Study of a <sup>68</sup>Ga-Functionalized Polymeric Cardiac Blood Pool Agent

  • Katayoun Saatchi,
  • François Bénard,
  • Navjit Hundal,
  • Joshua Grimes,
  • Sergey Shcherbinin,
  • Maral Pourghiasian,
  • Donald E. Brooks,
  • Anna Celler,
  • Urs O. Häfeli

DOI
https://doi.org/10.3390/pharmaceutics15030767
Journal volume & issue
Vol. 15, no. 3
p. 767

Abstract

Read online

Cardiac blood pool imaging is currently performed almost exclusively with 99mTc-based compounds and SPECT/CT imaging. Using a generator-based PET radioisotope has a few advantages, including not needing nuclear reactors to produce it, obtaining better resolution in humans, and potentially reducing the radiation dose to the patient. When the shortlived radioisotope 68Ga is used, it can be applied repeatedly on the same day—for example, for the detection of bleeding. Our objective was to prepare and evaluate a long-circulating polymer functionalized with gallium for its biodistribution, toxicity, and dosimetric properties. A 500 kDa hyperbranched polyglycerol was conjugated to the chelator NOTA and radiolabeled rapidly at room temperature with 68Ga. It was then injected intravenously into a rat, and gated imaging allowed us to easily observe wall motion and cardiac contractility, confirming the suitability of this radiopharmaceutical for cardiac blood pool imaging. Internal radiation dose calculations showed that the radiation doses that patients would receive from the PET agent would be 2.5× lower than those from the 99mTc agent. A complete 14-day toxicology study in rats concluded that there were no gross pathology findings, changes in body or organ weights, or histopathological events. This radioactive-metal-functionalized polymer might be a suitable non-toxic agent to advance for clinical application.

Keywords